View in EDS

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Authors: Nikolcheva T; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland. Electronic address: tania.nikolcheva@roche.com., Pagano G; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland; University of Exeter Medical School, London, UK., Anzures-Cabrera J; Roche Products, Welwyn Garden City, UK., Trundell D; Roche Products, Welwyn Garden City, UK., Kustermann T; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland., Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Marek K; Institute for Neurodegenerative Disorders, New Haven, CT, USA., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK., Seppi K; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria., Stocchi F; Department of Neurology, University San Raffaele Roma and the Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome., Postuma RB; Department of Neurology, McGill University, Montreal, QC, Canada; Montreal Neurological Institute, Montreal, QC Canada., Pross N; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Monnet A; Product Development Data Science, F Hoffmann-La Roche, Basel, Switzerland., Respondek G; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Schlegel V; Product Development Safety, F Hoffmann-La Roche, Basel, Switzerland., Boak L; Global Product Strategy, F Hoffmann-La Roche, Basel, Switzerland., Rutten-Jacobs L; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Kerchner GA; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland., Brundin P; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland., Svoboda H; Global Product Strategy, F Hoffmann-La Roche, Basel, Switzerland., Bonni A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland.
Corporate Authors: PADOVA Investigators, Prasinezumab Study Group
Source: Lancet (London, England) [Lancet] 2026 May 30; Vol. 407 (10544), pp. 2227-2240.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42208564
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Nikolcheva+T%22">Nikolcheva T</searchLink>; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland. Electronic address: tania.nikolcheva@roche.com.<br /><searchLink fieldCode="AU" term="%22Pagano+G%22">Pagano G</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland; University of Exeter Medical School, London, UK.<br /><searchLink fieldCode="AU" term="%22Anzures-Cabrera+J%22">Anzures-Cabrera J</searchLink>; Roche Products, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Trundell+D%22">Trundell D</searchLink>; Roche Products, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Kustermann+T%22">Kustermann T</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Simuni+T%22">Simuni T</searchLink>; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Marek+K%22">Marek K</searchLink>; Institute for Neurodegenerative Disorders, New Haven, CT, USA.<br /><searchLink fieldCode="AU" term="%22Pavese+N%22">Pavese N</searchLink>; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.<br /><searchLink fieldCode="AU" term="%22Seppi+K%22">Seppi K</searchLink>; Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.<br /><searchLink fieldCode="AU" term="%22Stocchi+F%22">Stocchi F</searchLink>; Department of Neurology, University San Raffaele Roma and the Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome.<br /><searchLink fieldCode="AU" term="%22Postuma+RB%22">Postuma RB</searchLink>; Department of Neurology, McGill University, Montreal, QC, Canada; Montreal Neurological Institute, Montreal, QC Canada.<br /><searchLink fieldCode="AU" term="%22Pross+N%22">Pross N</searchLink>; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Monnet+A%22">Monnet A</searchLink>; Product Development Data Science, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Respondek+G%22">Respondek G</searchLink>; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schlegel+V%22">Schlegel V</searchLink>; Product Development Safety, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Boak+L%22">Boak L</searchLink>; Global Product Strategy, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Rutten-Jacobs+L%22">Rutten-Jacobs L</searchLink>; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kerchner+GA%22">Kerchner GA</searchLink>; Product Development Neurology, Roche Pharma Development, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Brundin+P%22">Brundin P</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Svoboda+H%22">Svoboda H</searchLink>; Global Product Strategy, F Hoffmann-La Roche, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bonni+A%22">Bonni A</searchLink>; Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F Hoffmann-La Roche, Basel, Switzerland.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22PADOVA+Investigators%22">PADOVA Investigators</searchLink><br /><searchLink fieldCode="CA" term="%22Prasinezumab+Study+Group%22">Prasinezumab Study Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2026 May 30; Vol. 407 (10544), pp. 2227-2240.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42208564
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(26)00865-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2227
    Titles:
      – TitleFull: Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Nikolcheva T
      – PersonEntity:
          Name:
            NameFull: Pagano G
      – PersonEntity:
          Name:
            NameFull: Anzures-Cabrera J
      – PersonEntity:
          Name:
            NameFull: Trundell D
      – PersonEntity:
          Name:
            NameFull: Kustermann T
      – PersonEntity:
          Name:
            NameFull: Simuni T
      – PersonEntity:
          Name:
            NameFull: Marek K
      – PersonEntity:
          Name:
            NameFull: Pavese N
      – PersonEntity:
          Name:
            NameFull: Seppi K
      – PersonEntity:
          Name:
            NameFull: Stocchi F
      – PersonEntity:
          Name:
            NameFull: Postuma RB
      – PersonEntity:
          Name:
            NameFull: Pross N
      – PersonEntity:
          Name:
            NameFull: Monnet A
      – PersonEntity:
          Name:
            NameFull: Respondek G
      – PersonEntity:
          Name:
            NameFull: Schlegel V
      – PersonEntity:
          Name:
            NameFull: Boak L
      – PersonEntity:
          Name:
            NameFull: Rutten-Jacobs L
      – PersonEntity:
          Name:
            NameFull: Kerchner GA
      – PersonEntity:
          Name:
            NameFull: Brundin P
      – PersonEntity:
          Name:
            NameFull: Svoboda H
      – PersonEntity:
          Name:
            NameFull: Bonni A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 05
              Text: 2026 May 30
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 407
            – Type: issue
              Value: 10544
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1